What this opportunity is
The U.S. Department of Health and Human Services, through the FDA, awarded a sole source, firm-fixed-price purchase order to Z-Spec, Inc. for specific analytical laboratory instruments, including the Z-max Analyzer and E-max PLUS Analyzer, along with necessary accessories. This opportunity does not have a set-aside for small businesses, meaning it is open to all business types, but is specifically suited for those capable of providing brand-name commercial products. As this is an award notice, interested parties should track similar opportunities rather than bid on this particular contract.
Analysis by Mindy, grounded in the SAM.gov notice.
Description
Post-Award Public Notice
Posted Pursuant to 41 U.S.C. § 2304(f)(5) and RFO FAR Subpart 6.3 / FAR 6.305
Notice Type: Award Notice — Justification for Other Than Full and Open Competition
Date Posted: 08/21/2026
Contract Award Date: 08/21/2026
SECTION 1 — CONTRACT INFORMATION
Field Information
Agency U.S. Department of Health and Human Services (HHS)
Contracting Activity U.S. Food and Drug Administration (FDA), OƯice of
Acquisitions and Grants Services (OAGS)
Contract Number 75F40126P00227
Contract Type Firm-Fixed-Price (FFP) Purchase Order
Contractor Name Z-Spec, Inc.
Contractor Address 15 Tech Valley Drive, Suite 110
East Greenbush, NY 12061
Contractor UEI SAM T3BAMJU1A835
Total Contract Value $ 123,075.00
Period of Performance 09/14/2026-09/13/2027
Place of Performance / Delivery U.S. Food and Drug Administration, College Park, MD
PSC Code 6640 — Laboratory Equipment and Supplies
NAICS Code 334516 — Analytical Laboratory Instrument
Manufacturing
Small Business Size Standard 1,000 Employees
-- 1 of 5 --
Field Information
Acquisition Procedure FAR Part 12 — Commercial Products and Commercial
Services (RFO)
SECTION 2 — STATUTORY AUTHORITY FOR OTHER THAN FULL AND OPEN
COMPETITION
This contract was awarded without full and open competition pursuant to the authority of:
41 U.S.C. § 3304(a)(1) — Only one responsible source and no other supplies or
services will satisfy agency requirements
RFO FAR 6.103-1 (formerly FAR 6.302-1) — Only one responsible source
SECTION 3 — DESCRIPTION OF SUPPLIES ACQUIRED
The FDA awarded a sole source, firm-fixed-price purchase order to Z-Spec, Inc. for the
acquisition of the following brand-name commercial instruments:
- Z-Spec, Inc. Part number (106-01) Z-max Analyzer
- Z-Spec, Inc. Part number (102-02) E-max PLUS Analyzer
- Accessories, including sample cups, sample prep kit, transporting case, food/plant
standards kit.
The instruments meet the following technical requirements:
1) System:
Detection Method: energy dispersive XRF
Optics: Doubly Curved Crystal (DCC) optics
Excitation: 17 keV excitation beam or greater
Power: compatible with standard U.S. 120V 60 Hz power
Portability:
Field-portable design (<10 kg) combined with high analytical sensitivity,
enabling both laboratory and on-site testing
-- 2 of 5 --
2) Sample Preparation
Samples will be provided as dried powders, and purchase should include
sample holders and/cup, along with XRF transparent film to hold powdered
sample.
3) Performance Specifications - Required Limits of Detection
Must meet ultra-low limits of detection for toxic elements (e.g., As, Cd, Hg, Pb,
Tl) required for FDA regulatory and research applications.
Element LOD required (ug/g)
As 0.03
Cd 0.04
Hg 0.06
Pb 0.06
Tl 0.06
4) Software and Data Management
Fundamental Parameters data model
Data Output: Integrated hardware/software architecture designed specifically
for food safety and contaminant analysis workflows and data should be
available for export in standard .txt or .csv formats
Connectivity: Ethernet, USB ports
The OƯice of Chemistry and Toxicology, Division of Bioanalytical Chemistry, Chemical
Contaminants Branch requires the purchase of two portable Mono-Chromatic High
Definition X-ray fluorescence spectrometers (mHD-XRF systems): the Z-max Analyzer and
the E-max PLUS Analyzer. In support of the FDA's public health mission, these systems will
support rapid analytical testing of foods, dietary supplements, cosmetics, and spices for
toxic elements including arsenic (As), cadmium (Cd), mercury (Hg) and lead (Pb) detection.
The analytical capabilities may be extended to include additional elements as needed.
SECTION 4 — RATIONALE FOR OTHER THAN FULL AND OPEN COMPETITION
A. Unique and Proprietary Technology
The Z-max and E-max PLUS Analyzers are proprietary instruments exclusively designed,
developed, and manufactured by Z-Spec, Inc. These instruments employ patented optical
and detection architectures that are unique to Z-Spec, Inc. and are protected by
-- 3 of 5 --
intellectual property rights. These technologies are not available from any other
manufacturer or source.
B. No Technically Equivalent Substitute
Market research conducted by the FDA prior to award confirmed that no other
commercially available XRF or elemental analysis instrument provides equivalent
analytical sensitivity, detection limits, and measurement methodology required to meet
the Government's specific technical requirements. Conventional energy-dispersive XRF
(EDXRF) instruments available from other manufacturers do not achieve the required
detection performance levels.
C. Only One Responsible Source
Z-Spec, Inc. is the only responsible source capable of providing the Z-max and E-max PLUS
Analyzers. No other vendor manufactures or supplies instruments of equivalent capability
that would satisfy the Government's minimum needs in terms of the technical
requirements.
SECTION 5 — EFFORTS TO OBTAIN COMPETITION
In accordance with RFO FAR 6.103-1 and prior to award, the FDA posted a Notice Of Intent
For A Sole Source Award on SAM.gov on 07/29/2026, providing all interested parties 15
calendar days to respond with capability statements or oƯers demonstrating the ability to
meet the Government's requirements.
No responses were received demonstrating the capability to meet the Government's
requirements.
Accordingly, the FDA determined that Z-Spec, Inc. is the only responsible source capable of
satisfying the Government's requirements and proceeded with a sole source award.
SECTION 6 — PRICE REASONABLENESS
The Contracting OƯicer determined that the price of $ 123,075.00 is fair and
reasonable based on comparison with the invoices provided by Z-Spec, Inc. of the same
instruments sold to other commercial entities.
SECTION 7 — MARKET RESEARCH
-- 4 of 5 --
Market research was conducted by the FDA in accordance with RFO FAR Part 10. The
market research confirmed that no other commercially available instrument meets the
Govern…
Source: SAM.gov, as posted. Verify the current solicitation before responding.